...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of International Medical Research >Evaluation of the anticoagulant effect and timing of the concomitant use of S-1 and warfarin
【24h】

Evaluation of the anticoagulant effect and timing of the concomitant use of S-1 and warfarin

机译：评估S-1和华法林同时使用的抗凝作用和时机

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objectives To evaluate the effects of the timing of warfarin (WF) administration in patients with gastric cancer who received S-1 oral chemotherapy. Methods This retrospective chart review collected patient data including the prothrombin time international normalized ratio (PT-INR). Patients were categorized into three groups based on the timing of WF administration in relation to S-1 oral chemotherapy: group A patients received WF before S-1 chemotherapy; group B patients started WF during S-1 chemotherapy; and group C patients started WF after completing S-1 chemotherapy. Results A total of 21 patients with gastric cancer were included in the study; group A ( n ?=?8), group B ( n ?=?10) and group C ( n ?=?3). Seven patients (88%) in group A, seven (70%) in group B and all of the patients (100%) in group C had >2.5 PT-INR. There was no significant difference in the time-to-exceed 2.5 PT-INR between groups A and B. Conclusions These findings suggest that the timing of WF use in relation to S-1 chemotherapy might not be an important factor for PT-INR, although the low patient numbers included in the study should be taken into consideration.
机译：目的评估华法林（WF）给药时间对接受S-1口服化疗的胃癌患者的影响。方法这项回顾性图表审查收集了包括凝血酶原时间国际标准化比率（PT-INR）在内的患者数据。根据与S-1口服化疗有关的WF给药时间，将患者分为三组：A组在S-1化疗之前接受WF; A组在S-1化疗之前接受WF。 B组患者在S-1化疗期间开始WF。 C组患者在完成S-1化疗后开始WF。结果共纳入21例胃癌患者。 A组（n≥3），B（n≥10）和C（n≥3）。 A组有7名患者（88％），B组有7名（70％），C组所有患者（100％）的PT-INR均大于2.5。 A组和B组之间超过2.5 PT-INR的时间没有显着差异。结论这些发现表明，与S-1化疗相关的WF使用时间可能不是PT-INR的重要因素，尽管应考虑该研究中患者人数较少。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号